PLoS One:神经影像技术揭示多发性硬化症个体认知损伤的分子机制

2013-11-05 佚名 生物谷

近日,来自凯斯勒基金会的研究者通过研究,揭示了多发性硬化症(MS)个体认知疲劳发生的分子机制,相关研究刊登于国际杂志PLoS ONE上,这项研究首次使用神经影像技术来调查研究个体的认知疲劳发生的过程。【原文下载】 认知疲劳源于脑力劳动,这项研究中,研究者利用三种神经影像技术来揭示和MS个体认知疲劳相关的神经回路,第一种方法是功能性磁共振成像(fMRI)技术,其可以帮助

近日,来自凯斯勒基金会的研究者通过研究,揭示了多发性硬化症(MS)个体认知疲劳发生的分子机制,相关研究刊登于国际杂志PLoS ONE上,这项研究首次使用神经影像技术来调查研究个体的认知疲劳发生的过程。【原文下载】

认知疲劳源于脑力劳动,这项研究中,研究者利用三种神经影像技术来揭示和MS个体认知疲劳相关的神经回路,第一种方法是功能性磁共振成像(fMRI)技术,其可以帮助研究者找到大脑中和任务及经历相关的大脑活性区域;第二种方法是弥散张量成像技术(DTI),其可以帮助研究者找到大脑白质区域;第三种技术是基于像素的形态测量学技术(VBM),其可以帮助研究者调查大脑的结构改变情况。

这三种技术可以被用于检测个体对认知疲劳的反应情况,包括疲劳特点以及疲劳的状态等。这项研究也是首次使用神经影像技术来调查和认知疲劳相关的上述两个方面。

研究者Helen M. Genova博士表示,我们使用了最为先进的神经影像学技术来研究自发疲劳和认识疲劳相关措施之间的关系,这项工作的重要之处就在于阐述了个体认知疲劳的主观感觉和特殊大脑区域之间的大脑活性相关,这就为我们开发相应的干预措施来缓解个体疲劳提供了一定的思路。

通过对认知疲劳相关的大脑区域的识别将帮助研究者重新开发新型的疗法以及对病理生理学进行重新定义,从而改善患者的生活质量及病情变化提供帮助。

原文出处:

Helen M. Genova; Venkateswaran Rajagopalan;John DeLuca;Abhijit Das; Allison Binder;Aparna Arjunan; Nancy Chiaravalloti; Glenn Wylie.Examination of Cognitive Fatigue in Multiple Sclerosis using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging.PLoS ONE 8(11): e78811. doi:10.1371/journal.pone.0078811.【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1889580, encodeId=34db188958061, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Tue Dec 31 21:30:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789552, encodeId=90481e89552ea, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Oct 21 11:30:00 CST 2014, time=2014-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982881, encodeId=df3a1982881b3, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed May 28 03:30:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985586, encodeId=612b19855863a, content=<a href='/topic/show?id=163d912365d' target=_blank style='color:#2F92EE;'>#认知损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91236, encryptionId=163d912365d, topicName=认知损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Dec 26 00:30:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019744, encodeId=8e8b2019e446a, content=<a href='/topic/show?id=5ecde428074' target=_blank style='color:#2F92EE;'>#神经影像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74280, encryptionId=5ecde428074, topicName=神经影像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ab72500038, createdName=124985dbm06(暂无昵称), createdTime=Mon May 26 06:30:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396792, encodeId=a5bf1396e920c, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 07 01:30:00 CST 2013, time=2013-11-07, status=1, ipAttribution=)]
    2013-12-31 jml2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1889580, encodeId=34db188958061, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Tue Dec 31 21:30:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789552, encodeId=90481e89552ea, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Oct 21 11:30:00 CST 2014, time=2014-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982881, encodeId=df3a1982881b3, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed May 28 03:30:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985586, encodeId=612b19855863a, content=<a href='/topic/show?id=163d912365d' target=_blank style='color:#2F92EE;'>#认知损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91236, encryptionId=163d912365d, topicName=认知损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Dec 26 00:30:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019744, encodeId=8e8b2019e446a, content=<a href='/topic/show?id=5ecde428074' target=_blank style='color:#2F92EE;'>#神经影像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74280, encryptionId=5ecde428074, topicName=神经影像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ab72500038, createdName=124985dbm06(暂无昵称), createdTime=Mon May 26 06:30:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396792, encodeId=a5bf1396e920c, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 07 01:30:00 CST 2013, time=2013-11-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1889580, encodeId=34db188958061, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Tue Dec 31 21:30:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789552, encodeId=90481e89552ea, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Oct 21 11:30:00 CST 2014, time=2014-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982881, encodeId=df3a1982881b3, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed May 28 03:30:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985586, encodeId=612b19855863a, content=<a href='/topic/show?id=163d912365d' target=_blank style='color:#2F92EE;'>#认知损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91236, encryptionId=163d912365d, topicName=认知损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Dec 26 00:30:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019744, encodeId=8e8b2019e446a, content=<a href='/topic/show?id=5ecde428074' target=_blank style='color:#2F92EE;'>#神经影像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74280, encryptionId=5ecde428074, topicName=神经影像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ab72500038, createdName=124985dbm06(暂无昵称), createdTime=Mon May 26 06:30:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396792, encodeId=a5bf1396e920c, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 07 01:30:00 CST 2013, time=2013-11-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1889580, encodeId=34db188958061, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Tue Dec 31 21:30:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789552, encodeId=90481e89552ea, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Oct 21 11:30:00 CST 2014, time=2014-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982881, encodeId=df3a1982881b3, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed May 28 03:30:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985586, encodeId=612b19855863a, content=<a href='/topic/show?id=163d912365d' target=_blank style='color:#2F92EE;'>#认知损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91236, encryptionId=163d912365d, topicName=认知损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Dec 26 00:30:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019744, encodeId=8e8b2019e446a, content=<a href='/topic/show?id=5ecde428074' target=_blank style='color:#2F92EE;'>#神经影像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74280, encryptionId=5ecde428074, topicName=神经影像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ab72500038, createdName=124985dbm06(暂无昵称), createdTime=Mon May 26 06:30:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396792, encodeId=a5bf1396e920c, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 07 01:30:00 CST 2013, time=2013-11-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1889580, encodeId=34db188958061, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Tue Dec 31 21:30:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789552, encodeId=90481e89552ea, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Oct 21 11:30:00 CST 2014, time=2014-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982881, encodeId=df3a1982881b3, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed May 28 03:30:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985586, encodeId=612b19855863a, content=<a href='/topic/show?id=163d912365d' target=_blank style='color:#2F92EE;'>#认知损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91236, encryptionId=163d912365d, topicName=认知损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Dec 26 00:30:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019744, encodeId=8e8b2019e446a, content=<a href='/topic/show?id=5ecde428074' target=_blank style='color:#2F92EE;'>#神经影像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74280, encryptionId=5ecde428074, topicName=神经影像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ab72500038, createdName=124985dbm06(暂无昵称), createdTime=Mon May 26 06:30:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396792, encodeId=a5bf1396e920c, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 07 01:30:00 CST 2013, time=2013-11-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1889580, encodeId=34db188958061, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Tue Dec 31 21:30:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789552, encodeId=90481e89552ea, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Oct 21 11:30:00 CST 2014, time=2014-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982881, encodeId=df3a1982881b3, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed May 28 03:30:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985586, encodeId=612b19855863a, content=<a href='/topic/show?id=163d912365d' target=_blank style='color:#2F92EE;'>#认知损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91236, encryptionId=163d912365d, topicName=认知损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Dec 26 00:30:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019744, encodeId=8e8b2019e446a, content=<a href='/topic/show?id=5ecde428074' target=_blank style='color:#2F92EE;'>#神经影像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74280, encryptionId=5ecde428074, topicName=神经影像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ab72500038, createdName=124985dbm06(暂无昵称), createdTime=Mon May 26 06:30:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396792, encodeId=a5bf1396e920c, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 07 01:30:00 CST 2013, time=2013-11-07, status=1, ipAttribution=)]

相关资讯

Neurology:新影像技术加速多发性硬化症研究

日前,加拿大英属哥伦比亚大学(UBC)该校科研人员开发出一种最新的核磁共振影像(MRI)技术,可以检测更加细微的多发性硬化症,为治疗提供了更新的手段。相关研究论文刊登在了近期出版的《神经病学》(Neurology)期刊上。 多发性硬化症发生,是当人的免疫细胞攻击髓磷脂,也就是环护神经纤维的阻隔层时,导致髓磷脂崩溃,阻遏神经元间的电信号传递,症状包括麻木、衰弱、失明、颤抖、头晕眼花和疲劳。

Nat Immuno:干扰素β/IFNAR1激活免疫机制

日前,来自澳洲莫纳什大学的科学家们通过研究获得了关于免疫反应早期阶段的新见解,这为从多发性硬化症到癌症等许多疾病开发治疗提供了一些新的途径。这项刊登在《自然免疫学》(Nature Immunology)杂志上的研究首次确定了,β干扰素(interferon beta, IFNβ)蛋白结合细胞并激活免疫反应的机制特征。 当身体检测到病毒或细菌感染时,干扰素β就会产生。对于身体的抵御能力来说,干

Nature:再生疗法治疗多发性硬化症

斯克里普斯研究所(The Scripps Research Institute,TSRI)科学家发现了一组能够用于治疗多发性硬化症(multiple sclerosis,MS)的药物。与显存治疗MS药物的机制不同,该新药物能够激活一组前体细胞用来修复MS中遭到破坏的神经纤维。 该发现的新药包括一种治疗PD的药物benztropine,该药单独治疗或结合其他MS疗法治疗

Diabetes Care:青少年DM患者多发性硬化症发病风险高

在儿童及青少年中,1型糖尿病和多发性硬化症(MS)是典型的自身免疫性疾病。为了评价1型糖尿病并发MS的情况(通过估计儿童和青少年糖尿病人群的MS相对风险来进行),并寻找可能的影响因素,来自德国慕尼黑大学医学院儿科的Bechtold博士等进行了一项研究,研究发现,儿童和青少年糖尿病人群并发MS的风险较高。移民背景和甲状腺抗体是预测MS发病率的独立风险指标,环境因素可调节个人并发这两种疾病的风险。研究

FDA批准Tecfidera治疗多发性硬化症

  美国食品药品管理局(FDA)已批准一种新的每日2次口服药物——富马酸二甲酯用于治疗复发缓解型多发性硬化症(RRMS)。   将以Tecfidera作为商品名上市的该药物被认为具有预防大脑氧化应激的作用。此外,试验证据表明,它还具有抗炎和神经保护剂的作用。   Tecfidera将成为众多已获批的MS治疗药物之一。根据美国多发性硬化症学会(NMSS)资料,两种剂型的干扰素β-1a(Avone

GSK暂停治疗多发性硬化症实验化合物的人体试验

葛兰素史克(GlaxoSmithKline, GSK)今天宣布,已暂停在人类志愿者身上试验一种治疗多发性硬化症的实验化合物,此前在科学论文中造假的指控导致该公司解雇其在中国的顶级研究员。 这家英国公司表示,正在复核 GSK 2618960 的数据,这是一种处于早期临床试验阶段的化合物,其作用机理在《自然医学》(Nature Medicine)杂志2010年发表的一篇论文中得到阐述。 3 月下旬